INHIBRX BIOSCIENCES INC

INBXNASDAQ

🏆 #2112 by market capEarnings Aug 12US Equity

$95.30▲ $3.01 (+3.16%)

Live

1h▲ 1.8%

24h▲ 3.2%

7d▲ 13.3%

14d▲ 20.0%

30d▲ 3.1%

1y▲ 347.1%

🏦Market Cap

$1.40B

Small Cap

📈Revenue Growth (YoY)

+550.0%

High Growth

📊Gross Margin

-80.4%

Thin

💵FCF Margin

-10148.9%

Thin

⚖️P/S Ratio

1042.6x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $94.58 – $96.15
52-Week Range: $22.04 – $155.29
Volume: $5.03B
Avg Volume: $5.64B
Shares Outstanding: 14.7M
Next Earnings: Oct 5, 2026

Fundamentals Snapshot

Annual Revenue: $1M
Last Q Revenue: $315,270
P/E Ratio: -11.0
P/S Ratio: 1042.6x
EPS (TTM): $-8.35
Dividend Yield: 0.00%

Why Investors Own INBX

✓High-growth profile — revenue up +11.3% YoY with expanding US Equity exposure.
✓Healthy economics — 56% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$1M▲ +6.9% YoY

Gross Margin (TTM)

55.6%▼ −0.5% YoY

Operating Income (TTM)

$457,600▲ +6.9% YoY

Free Cash Flow (TTM)

$314,600▲ +6.9% YoY

About INHIBRX BIOSCIENCES INC

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

🦦